N-(4-chlorobenzyl)-2-((2R,6S,E)-5,12-dioxo-2-phenyl-1-oxa-4-azacyclododec-8-en-6-yl)acetamide | 1132653-79-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: N-(4-chlorobenzyl)-2-((2R,6S,E)-5,12-dioxo-2-phenyl-1-oxa-4-azacyclododec-8-en-6-yl)acetamide
• 英文别名: Robotnikinin；N-[(4-chlorophenyl)methyl]-2-[(2R,6S,8E)-5,12-dioxo-2-phenyl-1-oxa-4-azacyclododec-8-en-6-yl]acetamide
• CAS: 1132653-79-2
• 化学式: C₂₅H₂₇ClN₂O₄
• 分子量: 454.953
• InChiKey: DRDSZZCLAHXSAE-BQIDRLATSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  84.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(4-chlorobenzyl)-2-((2R,6S,E)-5,12-dioxo-2-phenyl-1-oxa-4-azacyclododec-8-en-6-yl)acetamide 在 四氧化锇 、 4-甲基苯磺酸吡啶 、 N-甲基吗啉氧化物 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 、 叔丁醇 为溶剂， 反应 11.0h， 生成 N-(4-chlorobenzyl)-2-((3aS,8R,12S,13aS)-2,2-dimethyl-6,11-dioxo-8-phenyldecahydro-3aH-[1,3]dioxolo[4,5-h][1,4]oxaazacyclododecin-12-yl)acetamide
  参考文献：
  名称：

  SONIC HEDGEHOG MODULATORS

  摘要：

  索尼克刺猬调节剂及其使用方法已提供。

  公开号：

  US20140094462A1
• 作为产物：
  描述：

  (R)-α-(氨基甲基)苄醇 在 RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 1.0h， 生成 N-(4-chlorobenzyl)-2-((2R,6S,E)-5,12-dioxo-2-phenyl-1-oxa-4-azacyclododec-8-en-6-yl)acetamide
  参考文献：
  名称：

  [EN] SONIC HEDGEHOG MODULATORS
  [FR] MODULATEURS DE SONIC HEDGEHOG

  摘要：

  公开号：

  WO2009132032A3

文献信息

• Syntheses of aminoalcohol-derived macrocycles leading to a small-molecule binder to and inhibitor of Sonic Hedgehog
  作者：Lee F. Peng、Benjamin Z. Stanton、Nicole Maloof、Xiang Wang、Stuart L. Schreiber

  DOI：10.1016/j.bmcl.2009.09.089

  日期：2009.11

  We report the synthesis and biological activity of a library of aminoalcohol-derived macrocycles from which robotnikinin (17), a binder to and inhibitor of Sonic Hedgehog, was derived. Using an asymmetric alkylation to set a key stereocenter and an RCM reaction to close the macrocycle, we were able to synthesize compounds for testing. High-throughput screening via small-molecule microarray (SMM) technology led to the discovery of a compound capable of binding ShhN. Follow-up chemistry led to a library of macrocycles with enhanced biological activity relative to the original hit compounds. Differences in ring size and stereochemistry, leading to alterations in the mode of binding, may account for differences in the degree of biological activity. These compounds are the first ones reported that inhibit Shh signaling at the ShhN level. (C) 2009 Elsevier Ltd. All rights reserved.
• SHH Regulation and Methods Thereof
  申请人：Kottmann Andreas H.

  公开号：US20120082623A1

  公开（公告）日：2012-04-05

  The invention provides for methods of upregulating endogenous GDNF by inhibiting Shh signaling. The invention further provides a method for increasing the production of cholinergic neurons and dopamine neurons by subventricular zone (SVZ) neurogenesis in a subject. The invention further provides methods for treating a neurodegenerative disorder in a subject.
• METHOD FOR TREATING A DISEASE OR DISORDER OF THE LUNG BY INHIBITION OF THE HEDGEHOG PATHWAY
  申请人：AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

  公开号：US20150225476A1

  公开（公告）日：2015-08-13

  The present invention is directed to a method of treating a disease or disorder characterised by one or more of the following: decreased lung function, bronchial hyper-responsiveness, hypersecretion of mucus, epithelial cell hyperplasia, smooth muscle hypertrophy, fibrosis or inflammation with an antagonist of a Hedgehog protein, an antagonist of Smoothened, or an antagonist of Gli. The present invention further provides kits for implementing the above method and the use of an antagonist of a Hedge-hog protein, an antagonist of Smoothened, or an antagonist of Gli for treating the above disease or disorder.
• METHOD AND CULTURE MEDIUM FOR EX VIVO CULTURING OF EPIDERMIS-DERIVED STEM CELLS
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenchaften e.V.

  公开号：US20180282690A1

  公开（公告）日：2018-10-04

  The present invention relates to a method for culturing epidermis-derived stem cells comprising the step of culturing epidermis-derived stem cells in the presence of a three-dimensional extracellular matrix (3D-ECM) and a basal cell culture medium comprising: Epidermal Growth Factor (EGF); and/or a Vascular Endothelial Growth Factor (VEGF); and/or a Fibroblast Growth Factor (FGF); and further a ROCK (Rho-kinase) inhibitor. The present invention further relates to a method for ex vivo de novo generation of epidermis-derived stem cells. Furthermore, the present invention relates to an epidermis-derived stem cell that is obtainable by a method according to the present invention. Uses of said epidermis-derived stem cell, e.g. uses of said epidermis-derived stem cell for in vitro tissue production, in vitro drug discovery screening and medical applications, are also provided herein. The present invention further relates to a cell culture medium that is employed in the context of a method of the present invention.
• US8530456B2
  申请人：——

  公开号：US8530456B2

  公开（公告）日：2013-09-10